Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:14:37.644Z.
Consensus retrieved: 2026-10-06T15:26:10.444Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:14:37.644Z.
Quote observation: 2026-10-06T17:10:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Forward PE Ratio (N/A) = Dated Quote Price ($3.73) / Consensus Forward EPS ($-0.78)
FORWARD PE RATIO
N/A
Prelude Therapeutics Incorporated
Market Cap
$212.36M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $212.36M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $213.84M | 18.62 |
| Compugen Ltd. (CGEN)vs › | $210.38M | N/A |
| Alector, Inc. (ALEC)vs › | $209.84M | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $208.14M | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.87M | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.14M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.51M | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $206.10M | 20.89 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $221.16M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.73, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.78 | $-1.14 – $-0.42 | 3 | n/m |
| 2027-12-31 | $-0.43 | $-1.16 – $-0.10 | 2 | n/m |
| 2028-12-31 | $-0.10 | $-0.61 – $0.41 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
